Latest Articles
-
How Sensitive Is Pfizer’s Stock To Its Gross Margin?
At nearly 80%, Pfizer ‘s (NYSE:PFE) gross margin is among the industry’s best. The figure for rivals such as Merck (NYSE:MRK) and Bristol-Myers Squibb (NYSE:BMY) stands at around 75%, while Roche’s (NASDAQ:RHHBY) is similarly a...
-
A Look At Big Pharma’s Value Sensitivity To Changes In Tax Rates
With the U.S. government’s new tax law coming into effect, many companies will see a significant impact from changes in their effective tax rates (some more than others, of course). In this note, we focus on some of the major pharmaceutical...
-
Pfizer’s Neuroscience Drug Portfolio Looks More Or Less Mature
Pfizer (NYSE:PFE) recently announced that it will end research into new drugs for Alzheimer’s and Parkinson’s diseases, resulting in 300 layoffs from its Neuroscience segment. Neuroscience drugs account for just around 5% of the comp...
-
How Will Pfizer’s Oncology Segment Shape Up In The Coming Years?
Pfizer’s (NYSE:PFE) Oncology segment accounts for roughly 20% of the company’s value, according to our estimates. Pfizer hadn’t seen significant growth in its Oncology segment until recent years with Ibrance. Most of the company̵...
-
A Quick Look At Merck & Pfizer’s New Diabetes Drug
Pfizer (NYSE:PFE) and Merck (NYSE:MRK) recently launched their jointly-developed diabetes drug Ertugliflozin. The drug will be marketed under the name Steglatro, and marks the companies’ foray in the SGLT2 inhibitor market. Ertugliflozin w...
-
A Closer Look At Pfizer’s Phase 3 Pipeline
We estimate that Pfizer’s (NYSE:PFE) phase 3 drug pipeline (not counting the enhancement of currently marketed products) can be worth as much as $50 billion, or nearly 25% of its current market value. Most of this value is likely to be rea...
-
Pfizer’s Bet On Oncology
Pfizer’s (NYSE:PFE) Oncology segment accounts for less than 20% of the company’s value, according to our estimates. For most other major pharma companies, their oncology portfolios are larger contributors to their top lines, and it a...
-
The Outlook For Pfizer’s Anti-Infective Drugs Business
Pfizer’s (NYSE:PFE) anti-infective drugs account for close to 12% of the company’s value, according to our estimates. Most of this value can be attributed to a single drug family – Prevnar. The company has 10 drugs in its anti-...
-
How Large Is Pfizer’s Biosimilar Opportunity?
Roche (NASDAQ:RHHBY) recently sued Pfizer (NYSE:PFE), stating that the latter’s biosimilar for Herceptin amounts to patent infringement . Roche has nearly $2.5 billion in sales at stake. We believe that these lawsuits are going to be inc...
-
Prevnar Helps Pfizer Post Better Than Expected Q3 Results
Pfizer’s (NYSE:PFE) recently released Q3 results were above street estimates, led by higher than expected sales of Prevnar. The company also raised its full year earnings guidance to $2.54 – $2.62 per share. Trefis currently estimate...
-
Bavencio’s EU Nod A Positive For Pfizer’s Oncology Business
Pfizer (NYSE:PFE) has co-developed an anti-PD L1 cancer drug Bavencio (avelumab) with Merck, which has now been granted approval to treat a rare and aggressive type of skin cancer called Merkel cell carcinoma (MCC) from European regulators. Earl...
-
Pfizer: Some Near Term Challenges May Mute Positive Triggers
The impact of Pfizer ‘s (NYSE:PFE) second quarter results on the company’s stock was barely noticeable, and this has almost become a norm. The company’s stock has remained largely rangebound for the last five years despite Pfize...
-
Pfizer’s Exit From Brazil Generics Market Is Not Alarming
Pfizer (NYSE:PFE) recently relinquished its stake in Brazilian generics maker Laboratório Teuto Brasileiro for just 30 cents total. In 2010, Pfizer invested nearly $240 million in the company and acquired a 40% stake in the process. Clearly, the...
-
Why Investment In Biosimilars Is Important For Pfizer
Pfizer (NYSE:PFE) bought Hospira in 2015 to strengthen its generic drugs business, and gain a strong foothold in sterile injectables and the growing biosimilar market. It is Hospira’s biosimilar pipeline that holds to the most promise as f...
-
Will Pfizer Be Affected By Trump Administration Tax Reform?
The Trump administration’s tax reform is eagerly awaited by the corporate world, as it proposes to lower the corporate tax rate to 15%. A lower corporate tax rate would allow companies to potentially increase investments with freed up cash,...
